IPP Bureau
Jubilant Pharmova recovers: ICICI Securities
By IPP Bureau - February 13, 2021
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Approval accorded under PLI Scheme for domestic manufacturing of medical devices
By IPP Bureau - February 12, 2021
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Glenmark receives ANDA approval for Clindamycin Phosphate Gel
By IPP Bureau - February 12, 2021
According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.
LupinLife Launches ayurvedic energy supplement
By IPP Bureau - February 12, 2021
Be One is a 100% Ayurvedic health and wellness supplement.
.jpg "ICN to organise E-conference on India's Pharma Industry Outlook on Feb 12")
ICN to organise E-conference on India's Pharma Industry Outlook on Feb 12
By IPP Bureau - February 11, 2021
Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.
Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
By IPP Bureau - February 11, 2021
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
SMS Pharmaceuticals Q3FY21 consolidated PAT up to Rs. 21.39 Cr
By IPP Bureau - February 11, 2021
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
Sun Pharma Advanced Research Q3FY21 loss at Rs. 67.62 crore
By IPP Bureau - February 11, 2021
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
J B Chemicals & Pharmaceuticals Q3FY 21 consolidated PAT up at Rs. 151.66 Cr
By IPP Bureau - February 11, 2021
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
Lupin receives approval for tavaborole topical solution
By IPP Bureau - February 10, 2021
Tavaborole Topical Solution, 5%, is an oxaborole antifungal.
Jubilant Pharmova Q3FY21 consolidated PAT at Rs. 309.93 Cr
By IPP Bureau - February 08, 2021
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
Zydus completes enrolment for two Phase Ill trials of Desidustat
By IPP Bureau - February 08, 2021
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr
By IPP Bureau - February 06, 2021
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
Pfizer registers Q3FY21 PAT at Rs. 141.24 Cr
By IPP Bureau - February 06, 2021
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr
By IPP Bureau - February 06, 2021
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
